Description: Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Europe, the Nordic region, the United States, and the rest of the world. The company's products portfolio includes Remetinostat, which has completed Phase II clinical study for use in the treatment of cutaneous T-cell lymphoma; Birinapant in combination with Keytruda that is in phase I/II study for treating solid tumors; and MIV-711, which is in Phase IIa study that is used for the treatment of osteoarthritis, as well as MIV-818, a preclinical stage nucleoside pro-drug for treating patients with advanced liver cancers. Its products also include Xerclear for use in the treatment of labial herpes in Europe and the rest of the world; MIV-802, a pan-genotypic nucleotide-based inhibitor of the hepatitis C virus NS5B polymerase, which is in preclinical development in Greater China; and Simeprevir/OLYSIO, an antiviral combination treatment regimen for chronic genotype 1 and 4 hepatitis C infection in adult patients with liver disease, including cirrhosis. Medivir AB (publ) was founded in 1988 and is headquartered in Huddinge, Sweden.
Home Page: www.medivir.com
Lunastigen 5
Huddinge,
Sweden
Phone:
46 8 54 68 31 00
Officers
| Name | Title |
|---|---|
| Mr. Magnus Christensen | Chief Financial Officer |
| Mr. Jens Lindberg | Chief Exec. Officer |
| Mr. Fredrik Öberg | Chief Scientific Officer & Chief Medical Officer |
| Dr. Thomas Morris | Interim Chief Medical Officer |
| Karin Tunblad | Sr. Principal Scientist & MIV-818 Project Leader |
Exchange: OTCGREY
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0245 |
| Price-to-Sales TTM: | 26.5713 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |